BIOMARIN PHARMACEUTICAL INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BMRN in the last 30 days.
See all $BMRN insider activity →BioMarin Pharmaceutical (BMRN) has agreed to a $490 million deal for a program targeting a rare bone disease. The acquisition is aimed at expanding the company's portfolio in the rare disease space, according to the company.
Ultragenyx (RARE) and Regeneron (REGN) received FDA approvals for GENGLYCOS and Pasatru, respectively. BioMarin (BMRN) acquired Alesta for $490M. Humacyte (HUMA) and Eyepoint (EYPT) faced trial setbacks. Key financials: RARE -$25.32, REGN -$826.64, BMRN -$67.68, HUMA -$0.68.
BioMarin Pharmaceutical (BMRN) rose 6.9% after Q2 results. Myriad Genetics (MYGN) fell 41.8% with revenue down 10.5% YoY, missing estimates. Halozyme Therapeutics (HALO) gained 25% with revenue up 47.7% YoY, beating expectations. Vertex Pharmaceuticals (VRTX) increased 16.3% with revenue up 12.5% YoY, topping forecasts.
Over the past 7 days, alphai's AI scored 1 news story mentioning BMRN (BIOMARIN PHARMACEUTICAL INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent BMRN coverage spans mergers & acquisitions, corporate actions and regulation.
Deal could boost revenue outlook and share price.
Acquisition expands BioMarin's rare‑disease pipeline and may be accretive.
BioMarin's Q2 performance is the focus of the article, indicating market interest.
The deal expands BioMarin's pipeline with ALE1 for hypophosphatasia, potentially boosting future revenue.
New rating and target may push the stock higher.
alphai scores every news story that mentions BMRN with an AI model for sentiment and relevance, and aggregates insider trades from BIOMARIN PHARMACEUTICAL INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
BioMarin Pharmaceutical (BMRN) has agreed to a $490 million deal for a program targeting a rare bone disease. The acquisition is aimed at expanding the company's portfolio in the rare disease space, according to the company.
1 min readUltragenyx (RARE) and Regeneron (REGN) received FDA approvals for GENGLYCOS and Pasatru, respectively. BioMarin (BMRN) acquired Alesta for $490M. Humacyte (HUMA) and Eyepoint (EYPT) faced trial setbacks. Key financials: RARE -$25.32, REGN -$826.64, BMRN -$67.68, HUMA -$0.68.
3 min readBioMarin Pharmaceutical (BMRN) rose 6.9% after Q2 results. Myriad Genetics (MYGN) fell 41.8% with revenue down 10.5% YoY, missing estimates. Halozyme Therapeutics (HALO) gained 25% with revenue up 47.7% YoY, beating expectations. Vertex Pharmaceuticals (VRTX) increased 16.3% with revenue up 12.5% YoY, topping forecasts.
3 min readBioMarin Pharmaceutical (BMRN) rose 3.5% after acquiring Alesta Therapeutics for $275M upfront, with up to $215M in milestones. Analysts reacted positively, with Barclays and Piper Sandler raising price targets. The stock closed at $69.33, near its 52-week high.
2 min readBMO Capital initiated coverage on Alnylam Pharmaceuticals (ALNY) with an Outperform rating and $318 price target, BioMarin Pharmaceutical (BMRN) with an Outperform rating and $98 target, and Ionis Pharmaceuticals (IONS) with a Market Perform rating and $60 target. Cantor Fitzgerald initiated Agomab Therapeutics (AGMB) with an Overweight rating. CLSA initiated KE Holdings (BEKE) with an Outperform rating and $23.8 target.
2 min readBioMarin Pharmaceutical (NASDAQ:BMRN) shares rose 4.7% premarket after it agreed to acquire Alesta Therapeutics for $275 million upfront, plus up to $215 million in milestone payments, to gain access to ALE1 for hypophosphatasia. Alesta will spin out non-ALE1 assets before closing, funded with cash on hand, with updated 2026 guidance after a likely Q2 close.
4 min readBioMarin Pharmaceutical (Nasdaq: BMRN) agreed to acquire Alesta Therapeutics to obtain ALE1, a Phase 1/2a oral small-molecule for hypophosphatasia. BioMarin will pay $275 million upfront plus up to $215 million in development and regulatory milestones. Alesta will spin out non-ALE1 assets before closing, expected this quarter. BioMarin plans updated 2026 guidance.
4 min readBIOMARIN PHARMACEUTICAL INC (BMRN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Contacts: Investors Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media Erin Rau BioMarin Pharmaceutical Inc. (925) 683-9622 BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Cli
3 min readBioMarin (NASDAQ:BMRN) said it expects to reach a leverage ratio below 2.5x about a year earlier than planned, targeting mid-next year. It estimates peak revenues of $1.4B for Galafold and $1.2B for Pombiliti/Opfolda in the mid-to-late 2030s, plus synergies about 50% of Amicus legacy costs. BioMarin raised VOXZOGO revenue guidance to at least $1B and reported 14% Q1 growth.
6 min readBioMarin Pharmaceutical (BMRN) shares rose about 2.6% in the morning after Canaccord Genuity raised its price target to $114 from $111 and kept a Buy rating. The update cited BioMarin’s strong Q2 2026 results and raised fiscal 2026 guidance for total revenue, Voxzogo revenue, and non-GAAP EPS. Shares traded around $65.91.
3 min read
